General article

• Safety of the newer disease-modifying agents for multiple sclerosis: disproportionality analysis in the FDA Adverse Events Reporting System database.

  Vasiliki Nikolopoulou, Spyridon Siafis, Antonios Milonas, Dimitrios Kouvelas, Georgios Papazisis

  81-93

  • PDF
• Randomized Controlled Trials: The case of Multiple Sclerosis - Refining the constraints of a treasure, a short outline

  Theodoros S. Constantinidis

  93-103

  • PDF
• Is there a therapeutic potential for repetitive Transcranial Magnetic Stimulation (rTMS) in the management of cognitive impairment in Multiple Sclerosis?

  Grigorios Nasios, Lambros Messinis

  104-109

  • PDF
• Does multiple sclerosis cause progressive and widespread cognitive decline?

  Marina Katsari, Dimitrios Kasselimis, Georgios Koutsis, Constantin Potagas

  110-115

  • PDF
• Is psychosis, at least in part, an immune-related dysmyelination disease?

  Orestis Giotakos

  116-129

  • PDF